Kindred Biosciences Releases Positive Results of Pilot Field Study of KIND-010 for the Management of Weight in Cats

SAN FRANCISCO, Jan. 26, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today released positive results from its pilot field study (KB104P) of KIND-010 for the management of weight in cats. It also announced successful completion of the sample size reassessment of the ongoing pivotal study.

This study was a randomized, single-blind, placebo-controlled study that enrolled 32 cats (16 in the KIND-010 group, 16 in the placebo group). The objective was to demonstrate the effectiveness and safety of KIND-010 for the stimulation of weight gain in cats under clinical conditions. At Week 2, mean weight of cats in the KIND-010 group was 4.32 kg (percent increase from Day 1 was 3.25%) versus 3.98 kg (percent increase from Day 1 was -1.65%) in the placebo group (p=0.0042).

KindredBio also announced that the pivotal effectiveness study (KB105) for KIND-010 for the management of weight loss in cats is over halfway enrolled, ahead of schedule. This randomized, double-blind, placebo-controlled study was concurred upon by FDA and will enroll a minimum of 200 cats (100 KIND-010/100 placebo) to assess the mean percent change in body weight from Day 1 to Week 2. The Company conducted a pre-specified, interim sample-size reassessment once over 100 cats were enrolled and determined that the original sample size does not need to be increased.

Richard Chin, M.D., President and Chief Executive Officer, stated, "We are very pleased to release the positive results from the pilot KIND-010 study and the interim sample-size reassessment. Weight loss in cats is a major unmet medical need, and we look forward to further progress."

About Kindred Biosciences

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

Contact

Russell Radefeld KindredBio [email protected] (650) 701-7904